Biogen (BIIB) PT Raised at Jefferies Following National Hemophilia Foundation Meeting
Tweet Send to a Friend
Jefferies analyst Thomas Wei reiterated a Buy rating on Biogen (NASDAQ: BIIB) and raised his price target from $266 to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
